Clinical Trial

Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2023 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin/tazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.
Trial Details
NCT Number NCT06076200
Lead Sponsor Shandong University
Collaborators: Shandong Provincial Hospital
Conditions Early-Onset Neonatal Sepsis
Enrollment 50 participants
Start Date 2023-09-30
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-10-10